Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
DNA$12.37+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share data)
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $944,073 | $1,315,792 |
| Accounts receivable, net | 17,157 | 80,907 |
| Accounts receivable - related parties | 742 | 1,558 |
| Prepaid expenses and other current assets | 39,777 | 51,822 |
| Total current assets | 1,001,749 | 1,450,079 |
| Property, plant and equipment, net | 188,193 | 314,773 |
| Operating lease right-of-use assets | 206,801 | 400,762 |
| Investments | 78,565 | 112,188 |
| Equity method investments | — | 1,543 |
| Intangible assets, net | 82,741 | 111,041 |
| Goodwill | 49,238 | 60,210 |
| Other non-current assets | 58,055 | 88,725 |
| Total assets | $1,665,342 | $2,539,321 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $9,323 | $10,451 |
| Deferred revenue (includes $5,426 and $10,309 from related parties) | 44,486 | 47,817 |
| Accrued expenses and other current liabilities | 110,051 | 114,694 |
| Total current liabilities | 163,860 | 172,962 |
| Non-current liabilities: | ||
| Deferred revenue, net of current portion (includes $119,053 and $131,188 from related parties) | 158,062 | 174,767 |
| Operating lease liabilities, non-current | 221,835 | 413,256 |
| Warrant liabilities | 5,700 | 10,868 |
| Other non-current liabilities | 18,733 | 31,191 |
| Total liabilities | 568,190 | 803,044 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 12) | 199 | 190 |
| Additional paid-in capital | 6,385,997 | 6,136,378 |
| Accumulated deficit | (5,290,528) | (4,397,659) |
| Accumulated other comprehensive income (loss) | 1,484 | (2,632) |
| Total stockholders’ equity | 1,097,152 | 1,736,277 |
| Total liabilities and stockholders’ equity | $1,665,342 | $2,539,321 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.